Present and Future Research on Anal Squamous Cell Carcinoma
Squamous cell carcinoma of the anus is an orphan disease, and after more than three decades of no substantial advances in disease knowledge and treatment, it is finally gaining momentum with the arrival of a taxane-based chemotherapy and immunotherapy. Currently, about 20 combination clinical trials...
Main Authors: | Laurie Spehner, Jihane Boustani, Luc Cabel, Jérôme Doyen, Angélique Vienot, Christophe Borg, Stefano Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/15/3895 |
Similar Items
-
Anti-Telomerase CD4<sup>+</sup> Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
by: Laurie Spehner, et al.
Published: (2020-09-01) -
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
by: Stefano Kim, et al.
Published: (2020-04-01) -
Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal
by: Angélique Saint, et al.
Published: (2019-11-01) -
Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study
by: Christina Glismand Truelsen, et al.
Published: (2021-05-01) -
Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
by: Faisal Shahjehan, et al.
Published: (2019-09-01)